Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

Abstract

In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .

• Authors: Jeffrey T Schouten, Amy Krambrink, Heather J Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R Kuritzkes, Roy M Gulick
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 50 Issue 5 Pg. 787-91 (Mar 01 2010) ISSN: 1537-6591 [Electronic] United States
• PMID: 20121419 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Alkynes
• Antiviral Agents
• Benzoxazines
• Cyclopropanes
• Nevirapine
• efavirenz

Topics

• Acquired Immunodeficiency Syndrome (drug therapy)
• Adult
• Alkynes
• Antiviral Agents (adverse effects, therapeutic use)
• Benzoxazines (adverse effects, therapeutic use)
• Cyclopropanes
• Female
• Humans
• Liver (drug effects)
• Male
• Middle Aged
• Nevirapine (adverse effects, therapeutic use)
• Withholding Treatment